Vasodilator Drugs: Chronic Vasodilator Therapy - Other Vasodilators
General (including evidence of efficacy)
Other orally administered vasodilators
Calcium channel blockers
Available studies including several multicenter controlled trials have not determined a role for their application in dilated cardiomyopathy (ischemic and nonischemic) and heart failure. The results either show no net effect or a detrimental effect on the clinical course. This applies to the dihydropyridines (e.g., nifedipine, amlodipine) and diltiazem. Although studies in diastolic heart failure are limited at the present time, there is little to suggest a role for calcium channel blockers for this patient group.
Large multicenter controlled trials are not available for sildenafil and thus this drug is not approved for use in heart failure. Initial small reports indicate that this agent may have a role in heart failure with or without concomitant pulmonary hypertension. In these early preliminary studies in heart failure, sildenafil improves exercise capacity, quality of life, and perhaps diastolic performance.
Pentoxifylline, perhexiline, and trimetazidine are awaiting large multicenter trials to establish effectiveness and potentially a role in the management of heart failure.
What's the Evidence?
Cohn, JN, Ziesche, S, Smith, R. " Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patient with chronic heart failure treated with enalapril: V-HeFT III". Circulation. vol. 96. 1997. pp. 856-863.(This is just one of many large controlled trials showing that calcium-channel blocking agents are of limited value in the management of chronic systolic heart failure.)
Lewis, GD, Shah, R, Shahzad, K. " Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension". Circulation. vol. 116. 2007. pp. 1555-1562.(A preliminary placebo-controlled study showing that another vasodilator with some promise, sildenafil, may have a beneficial effect on symptoms and exercise performance.)
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC
- Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC